Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J. Weiß(University of North Carolina at Chapel Hill), K. Dragnev(Dartmouth–Hitchcock Medical Center), Rajesh Malik(Agennix (United States)), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Donald Richards(The US Oncology Network), Patrick J. Roberts(Argos Therapeutics (United States)), Anne Y. Lai(Triangle), Caio M. Rocha Lima(Spartanburg Regional Healthcare System), Petros Nikolinakos(University Cancer and Blood Center), John Hamm(Ontario Institute for Cancer Research), Steven R. Schuster(University of Colorado Hospital), Piotr Sawrycki(Provincial Polyclinical Hospital in Toruń), Wahid T. Hanna, Jessica A. Sorrentino(University of North Carolina at Chapel Hill), Tibor Csőszi, Marina Maglakelidze(Institute of Clinical Research), Maen Hussein(Sarah Cannon), Joyce Antal, Anna Łowczak(University of Warmia and Mazury in Olsztyn), Shannon R. Morris(Research Triangle Park Foundation), M. Dómine Gómez(Hospital Universitario Fundación Jiménez Díaz), J.T. Beck(Highlands Oncology Group), V.K. Chiu(University of New Mexico), Raid Aljumaily(Sarah Cannon), Lowell L. Hart(Florida Cancer Specialists & Research Institute), Ralph V. Boccia(Center for Cancer and Blood Disorders), S. Adler(Triangle), Robert J. Hoyer(Georgetown University), Iurie Bulat
Cited by 173
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k